However, the genotypes <i>TT</i> and <i>GT</i> of rs712 polymorphism in <i>KRAS</i> could contribute significantly to colon localization, node metastasis, poor differentiation and poor chemotherapy response in CRC patients in this sample population.
However, the let-7 rs712 G/T polymorphism was discovered to play a potential role in BC tumor metastasis; therefore, it may be employed as a new biomarker or therapy targeted towards resistant tumor metastasis.
Stratified analyses revealed that CRC patients with the let-7 KRAS rs712 TT genotype were more likely to have clinical stage III or IV disease (OR = 3.29, 95% CI, 1.32-8.20) and distant metastasis (OR = 4.70, 95% CI, 1.81-12.25).
Results demonstrated that TT genotype and T allele of rs712 were associated with the increased risk of CRC; the patients with GG genotype and G allele of rs61764370 had a shorter survival and a higher risk of relapse or metastasis of CRC.